



Syndax Pharmaceuticals, Inc.
Investor Relations Department
35 Gatehouse Drive
Building D, Floor 3
Waltham, MA 02451
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: SNDX

Last Trade:	9.45
Trade Time:	4:00 PM ET 02.21.18
Change:	0.18 (+1.942%)
Day Range	9.22 - 9.79
52-Week Range	7.41 - 15.70
Volume	199,521


Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Syndax Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Through our pipeline agents, entinostat, a late stage, class 1 specific HDAC inhibitor and SNDX-6352, a phase 1 anti-CSF-1R monoclonal antibody, we are determined to realize a future in which people with cancer live longer and better than ever before. Syndax corporate headquarters are in Waltham, MA.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- 02.01.18 [Syndax Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca](#)
- 01.10.18 [Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer](#)
- 11.11.17 [Syndax Pharmaceuticals Announces Presentation of Data from Immuno-oncology Clinical Trials at the Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting](#)
- 11.07.17 [Syndax Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Clinical and Business Update](#)
- 11.07.17 [Syndax to Present at the SITC 32nd Annual Scientific Meeting](#)

Financial Information [\[View all \]](#)

- [Third Quarter Financial Results](#)
- 03.14.17 [Annual Report \(10-K\)](#)
- 04.07.17 [Proxy Statement \(DEF 14A\)](#)
- 11.08.17 [Quarterly Report \(10-Q\)](#)
- 08.10.17 [Quarterly Report \(10-Q\)](#)
- 05.09.17 [Quarterly Report \(10-Q\)](#)